Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of P-Anisic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.80 |
| ▸ | CA2 | P00918 | 2/20 | 0.80 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | CES2 | O00748 | 2/20 | 0.57 |
| ▸ | CES1 | P23141 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | XDH | P47989 | 1/20 | 0.56 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.55 |
| ▸ | RXRA | P19793 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| P-Anisic Acid SCHEMBL1157044 | 0.89 | CA1 (1.00) | CA1CA2NPC1RAB9APOLB | |
| P-Anisic Acid SCHEMBL43335 | 0.89 | CA1 (1.00) | CA1CA2NPC1RAB9APOLB | |
| P-Anisic Acid SCHEMBL414716 | 0.87 | CA1 (0.95) | CA1CA2NPC1RAB9APOLB | |
| P-Anisic Acid SCHEMBL29790432 | 0.87 | CA1 (0.95) | CA1CA2NPC1RAB9APOLB | |
| P-Anisic Acid SCHEMBL15347432 | 0.87 | CA1 (0.95) | CA1CA2NPC1RAB9APOLB | |
| P-Anisic Acid SCHEMBL1043957 | 0.87 | CA1 (0.95) | CA1CA2NPC1RAB9APOLB | |
| P-Anisic Acid SCHEMBL846287 | 0.87 | CA1 (0.95) | CA1CA2NPC1RAB9APOLB | |
| P-Anisic Acid SCHEMBL38654440 | 0.87 | CA1 (0.95) | CA1CA2NPC1RAB9APOLB | |
| P-Anisic Acid SCHEMBL17891327 | 0.87 | CA1 (0.95) | CA1CA2NPC1RAB9APOLB | |
| P-Anisic Acid SCHEMBL15548197 | 0.87 | CA1 (0.95) | CA1CA2NPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1897867-B1 | COMPOUNDS USED FOR INTERRUPTING REUPTAKE OF 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE OR TREATING DISEASES SUCH AS DEPRESSION | Shandong luye pharmaceutical co ltd (CN) | 2017-02-15 | — | — | EP | disclosed |
| US-8487132-B2 | Compounds for inhibition of 5-hydroxytryptamine and norepinephrine reuptake or for treatment of depression disorders, their preparation processes and uses thereof | SHANDONG LUYE PHARMACEUTICAL CO. LTD. (CN) | 2013-07-16 | — | — | US | disclosed |
| US-20120190741-A1 | COMPOUNDS FOR INHIBITION OF 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE REUPTAKE OR FOR TREATMENT OF DEPRESSION DISORDERS, THEIR PREPARATION PROCESSES AND USES THEREOF | SHANDONG LUYE PHARMACEUTICAL CO. LTD. (CN) | 2012-07-26 | — | — | US | disclosed |
| US-8178724-B2 | Compounds for inhibition of 5-hydroxytryptamine and norepinephrine reuptake or for treatment of depression disorders, their preparation processes and uses thereof | SHANDONG LUYE PHARMACEUTICAL CO., LTD. (CN) | 2012-05-15 | — | — | US | disclosed |
| US-20090118368-A1 | COMPOUNDS FOR INHIBITION OF 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE REUPTAKE OR FOR TREATMENT OF DEPRESSION DISORDERS, THEIR PREPARATION PROCESSES AND USES THEREOF | Li, Youxin (CN) | 2009-05-07 | — | — | US | disclosed |
| EP-1897867-A1 | COMPOUNDS, PREPARATION PROCESS, AND USES THEREOF USED FOR INTERRUPTING REUPTAKE OF 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE OR TREATING DISEASES SUCH AS DEPRESSION ET AL. | SHANDONG LUYE PHARMACEUTICAL CO., LTD. (CN) | 2008-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118368-A1 | COMPOUNDS FOR INHIBITION OF 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE REUPTAKE OR FOR TREATMENT OF DEPRESSION DISORDERS, THEIR PREPARATION PROCESSES AND USES THEREOF | TPH1, SLC6A2, HTR1A | CA1 4346/4885CA2 4004/4885PDE4B 661/4885 |
| US-20120190741-A1 | COMPOUNDS FOR INHIBITION OF 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE REUPTAKE OR FOR TREATMENT OF DEPRESSION DISORDERS, THEIR PREPARATION PROCESSES AND USES THEREOF | TPH1, SLC6A2, HTR1A | CA1 4346/4885CA2 4004/4885PDE4B 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.